Refine
Has Fulltext
- yes (13)
Is part of the Bibliography
- yes (13)
Document Type
- Journal article (13)
Language
- English (13) (remove)
Keywords
- CXCR4 (3)
- chemokine receptor (3)
- positron emission tomography (3)
- HNSCC (2)
- in vivo imaging (2)
- lymphoma (2)
- microenvironment (2)
- mutations (2)
- Activation (1)
- Bruton Tyrosine Kinase (1)
- B‐cell lymphoma (1)
- C-Myc (1)
- CXCR4/SDF-1 (1)
- DEL(5Q) (1)
- DLBCL (1)
- DOTATOC (1)
- EGFR (1)
- FDG PET/CT (1)
- FLT-PET (1)
- Ibrutinib (1)
- Ligand (1)
- MDS (1)
- MYC (1)
- Malignancies (1)
- Multiple Myeloma (1)
- NF-KAPPA-B (1)
- PCI-32765 (1)
- PET/CT (1)
- PRRT (1)
- Pathway (1)
- Positronen-Emissions-Tomografie (1)
- Proliferation (1)
- Rho-GTPases (1)
- SSTR (1)
- SphK1 (1)
- TP53 mutations (1)
- Targeted Therapies (1)
- Tumor Microenvironment (1)
- USP9X (1)
- XIAP (1)
- [18F]Fluorodeoxythymidine (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{68}\)Ga-Pentixafor (1)
- activation (1)
- acute myeloid leukemia (1)
- apoptosis (1)
- apoptosis, Myc (1)
- aurora kinase A polymorphism (1)
- aurorakinase B (1)
- autologous transplantation (1)
- azacitidine (1)
- bone disease (1)
- cancer (1)
- cells (1)
- cetuximab (1)
- chemokine receptor-4 (1)
- cleavage (1)
- combined immunodeficiency (1)
- cycle (1)
- endothelial cells (1)
- glioblastoma (1)
- glutaminase inhibition (1)
- growth (1)
- helper T-cells (1)
- imaging (1)
- involvement (1)
- karyotype (1)
- leukemia (1)
- lymphoid-tissue (1)
- malignancies (1)
- messenger RNA (1)
- mice (1)
- mitosis (1)
- multiple myeloma (1)
- neuroendocrine tumor (1)
- niche (1)
- p53 expression (1)
- peptide receptor radionuclide therapy (1)
- positron emission tomography/computed tomography (1)
- prognosis (1)
- prognostic value (1)
- radiation (1)
- radiation-induced migration (1)
- roquin (1)
- scoring system (1)
- stem-cells (1)
- survival (1)
- target (1)
- therapeutic target (1)
- ubiquitin (1)
Institute
- Pathologisches Institut (13) (remove)
Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging
(2015)
Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [\(^{68}\)Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [\(^{68}\)Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [\(^{68}\)Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [\(^{68}\)Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.
Drug resistance is a significant obstacle in cancer treatment and therefore a frequent subject of research. Developed or primary resistance limits the treatment success of inhibitors of the B cell receptor (BCR) pathway in mantle cell lymphoma (MCL) patients. Recent research has highlighted the role of the nuclear factor-kappa B (NF kappa B) pathway in the context of resistance to BCR inhibitors in MCL. In this study, we analyzed the dependency of MCL cell lines on NF kappa B signaling and illustrated the ability of CD40L to activate the alternative NF kappa B pathway in MCL. This activation leads to independency of classical NF kappa B signaling and results in resistance to BCR inhibitors. Therefore, ligands (such as CD40L) and their activation of the alternative NF kappa B pathway have a major impact on the drug response in MCL. Furthermore, this study indicates a protective role for cells expressing specific ligands as microenvironmental niches for MCL cells and underlines the significance of therapeutically targeting alternative NF kappa B signaling in MCL.
Chemokine receptor-4 (CXCR4) has been reported to be overexpressed in glioblastoma (GBM) and to be associated with poor survival. This study investigated the feasibility of non-invasive CXCR4-directed imaging with positron emission tomography/computed tomography (PET/CT) using the radiolabelled chemokine receptor ligand \(^{68}\)Ga-Pentixafor.
15 patients with clinical suspicion on primary or recurrent glioblastoma (13 primary, 2 recurrent tumors) underwent \(^{68}\)Ga-Pentixafor-PET/CT for assessment of CXCR4 expression prior to surgery. O-(2-\(^{18}\)F-fluoroethyl)-L-tyrosine (\(^{18}\)F-FET) PET/CT images were available in 11/15 cases and were compared visually and semi-quantitatively (SUV\(_{max}\), SUV\(_{mean}\)). Tumor-to-background ratios (TBR) were calculated for both PET probes. \(^{68}\)Ga-Pentixafor-PET/CT results were also compared to histological CXCR4 expression on neuronavigated surgical samples.
\(^{68}\)Ga-Pentixafor-PET/CT was visually positive in 13/15 cases with SUV\(_{mean}\) and SUV\(_{max}\) of 3.0±1.5 and 3.9±2.0 respectively. Respective values for \(^{18}\)F-FET were 4.4±2.0 (SUV\(_{mean}\)) and 5.3±2.3 (SUV\(_{max}\)). TBR for SUV\(_{mean}\) and SUV\(_{max}\) were higher for \(^{68}\)Ga-Pentixafor than for \(^{18}\)F-FET (SUV\(_{mean}\) 154.0±90.7 vs. 4.1±1.3; SUV\(_{max}\) 70.3±44.0 and 3.8±1.2, p<0.01), respectively. Histological analysis confirmed CXCR4 expression in tumor areas with high \(^{68}\)Ga-Pentixafor uptake; regions of the same tumor without apparent \(^{68}\)Ga-Pentixafor uptake showed no or low receptor expression.
In this pilot study, \(^{68}\)Ga-Pentixafor retention has been observed in the vast majority of glioblastoma lesions and served as readout for non-invasive determination of CXCR4 expression. Given the paramount importance of the CXCR4/SDF-1 axis in tumor biology, \(^{68}\)Ga-Pentixafor-PET/CT might prove a useful tool for sensitive, non-invasive in-vivo quantification of CXCR4 as well as selection of patients who might benefit from CXCR4-directed therapy.